Aptuit And Chiesi Collaborate To Treat Idiopathic Pulmonary Fibrosis
Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated Discovery Project aimed at providing innovative drugs to treat Idiopathic Pulmonary Fibrosis.
Both parties will contribute scientifically, with Aptuit providing integrated early Discovery capabilities, including Medicinal Chemistry and Pharmacology, as well as Drug Metabolism and Pharmacokinetics, in order to identify promising compounds for further pre-clinical development.
Dr. Jonathan Goldman, Chief Executive Officer, Aptuit, stated, “This project builds upon the existing relationship between Chiesi and Aptuit in the field of Respiratory Drug Discovery. We are delighted to be working with Chiesi to identify early stage compounds that we hope will ultimately progress into innovative treatments for patients with this debilitating disease”.
Dr. Mark Parry Billings, Corporate Drug Development Head, Chiesi Farmaceutici, commented, “We are very pleased to announce the partnership with Aptuit. We share a common culture of scientific excellence and commitment to quality research and development. This alliance will allow our Project to progress effectively to the identification of lead compounds with a novel mechanism of action, leveraging our joint expertise in Respiratory drug discovery”.
Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.READ MORE
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019